AzTrials
AzTrials

Colorectal CancerDEMETRANCT05732623

Exogenous and Endogenous Risk Factors for Early-onset Colorectal Cancer

An observational study of Colorectal Cancer and Early Onset Colorectal Cancer, run by San Raffaele University at 8 sites in 6 countries.

Recruiting

Looking for participants now. Contact the study team or a site below to ask about taking part.

Sites and contacts
Official record
Search all trials

Trial summary

An increase in early-onset colorectal cancers (eoCRC), defined as a CRC before 50 years, is confirmed globally. CRC pathogenesis has been associated with several risk factors (family history, germline pathogenic variants, obesity, alcohol, physical activity, red meat, and a Western diet). Read more about this study

Who is it for?
Ages 18 to 49 yearsHealthy volunteers can take part
What is being tested?
Semi Quantitative Food Frequency Questionnaire (SQFFQ)
How many people
2,300 participants
Where
8 sitesin 6 countries
Study dates
5 Dec 2022to Jan 2035
How long will I take part?
10 Years
Phase
Observational
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 49 years
  • All sexes
  • Healthy volunteers accepted
  • Adult

Study population: at least 300 patients in total (100 at IRCCS San Raffaele Scientific Institute) with a recent diagnosis of eoCRC (diagnosis made within 2 years prior to enrollment), aged 18-49 years, will be prospectively recruited at least 600 Healthy controls (HCs) totally (200 at IRCCS San Raffaele Scientific Institute), matched by age (matching range ± 5 years) and sex with eoCRCs will be prospectively enrolled. Healthy volunteers will be mainly enrolled among workers within the participating hospital center, followed regularly by preventive medicine. This enrollment will be carried out by e-mail invitation disseminated through the hospital's official mailing list

Who may be able to join

  • All sexes eligible
  • (for Cases) eoCRC diagnosed between 18 and 49 years and confirmed by histology (biopsy or surgical specimen in case of surgery)
  • (for Controls) negative past and present history of cancer; negative fecal occult blood test (FOBT), or negative colonoscopy.

Who cannot join

  • CRC diagnosed at ≥ 50 years
  • Diseases that can modify the dietary regimen (celiac disease, diabetes)
  • Diseases that are known to predispose to eoCRC (personal past or recent history of inflammatory bowel disease, past history of pelvic irradiation)
  • Unable to give written consents and to fill in the electronic questionnaire

Trial locations and contacts

8 sites in 6 countries. Contact the study team or a site near you to ask about taking part.

Giulia Martina Cavestro, MD PhD contact

0226435508 ext. +39

cavestro.giuliamartina@hsr.it

8 sites in 6 countries

United States2 sites, 2 recruiting
  • Section of Gastroenterology, Hepatology, and Nutrition, Department of Medicine University of Chicago Medicine

    Chicago, Illinois, 60637

    Sonia Kupfer, skupfer@medicine.bsd.uchicago.edu

    Recruiting
  • Department of Medicine-Gastroenterology, Denver Veterans Affairs Medical Center, University of Colorado Hospital

    Denver, Colorado, 80045

    Swati Patel, Swati.Patel@cuanschutz.edu

    Recruiting

Other trials in United States

Germany2 sites, 2 recruiting
  • Department of General, Visceral and Transplant Surgery, Hospital of the University of Munich (LMU)

    Munich

    Florian Kuhn, MD, Florian.Kuehn@med.uni-muenchen.de

    Recruiting
  • Gabriela Moslein

    Wuppertal

    Gabriela Moslein, MD, gmoeslein@outlook.de

    Recruiting

Other trials in Germany

Finland1 site, 1 recruiting
  • Department of Gastrointestinal Surgery, Helsinki University Hospital

    Helsinki

    Toni T Seppala, tseppala@me.com

    Recruiting

Other trials in Finland

Italy1 site, 1 recruiting
  • Prof Giulia Martina Cavestro, MD PhD

    Milan, Lombardy, 20132

    Giulia Martina Cavestro, MD, PhD, 0226435508 ext. +39, cavestro.giuliamartina@hsr.it

    Marta Puzzono, MD

    Recruiting

Other trials in Italy

Norway1 site, 1 recruiting
  • Division of Cancer Medicine, Oslo University Hospital (OUS), Institute for Cancer Genetics and Informatics Norwegian Radium Hospital

    Oslo

    Mev Dominguez Valentin, mev.dominguez.valentin@rr-research.no

    Recruiting

Other trials in Norway

Spain1 site, 1 recruiting
  • Department of Gastroenterology, Hospital Clínic de Barcelona, University of Barcelona

    Barcelona

    Francesc Balaguer Prunès, FPRUNES@clinic.cat

    Recruiting

Other trials in Spain

About this study

Official title: Diet obEsity sMoking Epigenetics geneTics biomaRkers Physical Activity: An International Multicenter Case-control Study on Endogenous and Exogenous Risk Factors in Early-onset Colorectal Cancer

An increase in early-onset colorectal cancers (eoCRC), defined as a CRC before 50 years, is confirmed globally.

CRC pathogenesis has been associated with several risk factors (family history, germline pathogenic variants, obesity, alcohol, physical activity, red meat, and a Western diet).

Read more

Design: an international, multicenter, retrospective case-control study of prospectively enrolled patients; low-risk intervention study as it will perform a fecal occult blood test Endpoint: predictive power of a semi-quantitative food frequency questionnaire (SQFFQ) developed for eoCRC.

Cases: Patients with a recent diagnosis of eoCRC (within 2 years from enrollment).

Controls: matched by age (matching range ± 5 years) and sex. Healthy volunteers will be mainly enrolled among workers within the participating hospital center. The enrolled healthy volunteers will perform a fecal occult blood test.

Variables of interest: age, sex, ethnicity, BMI at the time of eoCRC diagnosis and at 18 years old, country, tobacco smoking at the time of eoCRC diagnosis and at 18 years old, sitting time, TV-viewing time, moderate-to-vigorous physical activity (MVPA), waist circumference (cm), home blood pressure levels (mmHg), fasting blood glucose (mg/dl), regular consumption of aspirin/NSAID, calcium and folate supplements, oral contraceptive agents, post-menopausal hormones and years of consumptions, if the filled questionnaire reflects diet for the last 5-10 years before.

Cases only: date of eoCRC diagnosis, symptoms at diagnosis, eoCRC localization, eoCRC stage, histological diagnosis, type of surgery, and date (if performed), chemotherapy and radiotherapy (if performed), vital status and duration of follow-up, family history of CRC and other cancers (uterus, ovary, stomach, small intestine, urinary tract/bladder/kidney, bile ducts, brain, pancreas, skin tumors), type of germline pathogenetic variant (if performed).

Before the case-control study, three non-consecutive 24-hour Dietary Recalls (24hDRs) will validate the SQFFQ.

The SQFFQ will be administered to the validation study group during three non-consecutive calls, including one non-weekday (30-minute 24-h-recall computer-aided personal interview).

Primary Objective To measure the relative risk of specific dietary and lifestyle factors (smoking habit, alcohol intake, physical activity) for early-onset colorectal cancer in countries where eoCRC incidence is increasing versus stable/decreasing

Read the detailed description

Background Firstly described in U.S. series, an increase in early-onset colorectal cancers (eoCRC), defined as CRC before 50 years, is confirmed globally.

CRC pathogenesis has been associated with several endogenous and exogenous associated risk factors, including family history of CRC, CRC-related germline pathogenic variants, obesity, alcohol habits, physical activity, red and processed meat and a Western diet. Two dietary patterns appear as exogenous and behavioral factors associated with either CRC prevention or predisposition: the 'healthy' pattern (high in fruits, vegetables, and whole grains or legumes, fish, and low-fat milk or dairy products) and the 'unhealthy' or 'Western dietary' pattern (high in red and processed meat, sugary drinks, refined grains, desserts). Above all, the Western diet is one of the most important CRC risk factors. In the Nurses' Health Study II, Western diet during adolescence was associated with the development of high-risk rectal adenomas later in life. In a meta-analysis of cohort studies, the Western dietary pattern conferred a relative risk (RR) of 1.12 for CRC, compared with a 0.89 RR for the healthy pattern. Conversely, the Mediterranean diet demonstrated a protective role in CRC development, confirmed in the EPIC cohort study.

Rationale Dietary, lifestyle, and anthropometric risk factors are still poorly understood in eoCRC patients, despite its established rising incidence. To date, scant studies, mostly case-control and only a few prospective ones, investigated the exogenous risk factors of eoCRCs and eoCRC precursors and identified high intake of alcohol and processed meat, sedentary lifestyle as potential eoCRC risk factors, and obesity as ambiguous one.

Primary Objective To compare the associations of specific dietary and lifestyle factors (smoking habit, alcohol intake, physical activity) and anthropometric factors between eoCRC patients and healthy age- and sex-matched controls in countries with increasing versus stable or decreasing early-onset colorectal cancer (eoCRC) incidence.

Secondary Objectives

  1. To validate the semi-quantitative food frequency questionnaire (SQFFQ);
  2. To evaluate the consistency of associations across cohorts in pairwise comparisons;
  3. To assess whether associations differ among specific population subgroups (e.g., sex, ethnicity, smoking habits, BMI, physical activity, family history of CRC).

Type of study SQFFQ validation study: three non-consecutive 24-hour Dietary Recalls (24hDRs) will validate the ad hoc designed and shared SQFFQ, as previously performed [28-29]. The SQFFQ will be administered to the validation study group during three non-consecutive calls, including one non-weekday (30 minutes 24-h-recall computer-aided personal interview).

Case-control study: an international, multicentre, retrospective case-control study of prospectively enrolled patients will be performed to evaluate the associations of dietary, anthropometric, lifestyle factors in eoCRC patients compared to age, and sex matched healthy controls.

This study is sub-classified as a low-risk intervention study as it will perform fecal occult blood test as an additional procedure in the control group.

Inclusion criteria All sexes eligible Cases: eoCRC diagnosed between 18 and 49 years and confirmed by histology (biopsy or surgical specimen in case of surgery) Controls: negative past and present history of cancer; negative fecal occult blood test (FOBT), or negative colonoscopy.

Exclusion criteria CRC diagnosed at ≥ 50 years Diseases that can modify the dietary regimen (celiac disease, diabetes) Diseases that are known to predispose to eoCRC (personal past or recent history of inflammatory bowel disease, past history of pelvic irradiation) Unable to give written consents and to fill in the electronic questionnaire

Sample size

SQFFQ Validation study:

  • 100 subjects from each country, free from overt disease and in equal numbers of each gender.

Case-control study:

  • At least 300 eoCRC patients in total;
  • At least 600 healthy age- (matching range ± 5 years) and sex-matched controls subjects in total.

Study Procedure and Study Flow-chart Starting from the signature of the informed consent by the subject/patient (or subject/patient's legal tutor), she/he will be considered enrolled in the study.

The PI will be the only Administrator of the online platform and the only one able to generate the access codes (username/password) assigned to the co-investigators.

Each co-investigator will register the enrolled subjects anonymously on the online platform (unique alphanumeric identification code - see below), obtaining a username/password assigned to the subject for survey completion.

The unique alphanumeric identification code (Subject ID number) will be assigned consecutively in increasing order starting from '001'. A screened subject/patient identification list will be kept by PI.

SQFFQ validation study:

One hundred volunteers from each country, free from overt disease and in equal numbers of each sex, will be enrolled for the semi-quantitative food frequency questionnaire (SQFFQ) validation study. Potential volunteers will be recruited through different recruitment strategies: mail drops, recruitment lists, and databases, primary care facilities as well as networks for young people and/or among people who work in the same hospital of the research team, regularly followed by preventive medicine.

An ad hoc-designed and shared online SQFFQ will be available to report the usual frequency of consumption of a detailed list of foods and beverages. Information collected concern types, amount and frequency of consumption of food and drinks, types of seasoning, and methods of cooking. The computer-administered instrument will allow the respondent to select the food consumed and the appropriate portion size from photographs on a screen reducing the burden of coding.

All volunteers will receive detailed oral and written information by members of the study team (following local practices).

Three non-consecutive 24-hour Dietary Recalls (24hDRs), including one non-weekday (30 minutes 24-h-recall computer-aided personal interview), will validate the SQFFQ [28-29].

Case-control study:

An international, multicentre, retrospective case-control study of prospectively enrolled patients will be performed to evaluate the associations of dietary, anthropometric, lifestyle factors in eoCRC patients compared to age, and sex matched healthy controls.

This study is sub-classified as a low-risk intervention study as it will perform fecal occult blood test as an additional procedure in the control group.

The study will recruit:

  • at least 300 patients in total (100 at IRCCS San Raffaele Scientific Institute) with a recent diagnosis of eoCRC (diagnosis made within 2 years prior to enrollment), aged 18-49 years, will be prospectively recruited. eoCRC patients will be primarily enrolled as referred by the participant unit. Each participant unit shall identify eoCRC patients through recruitment lists and databases, primary care facilities, as well as networks for young people. Retrospective data (dietary and lifestyle factors) related to the 2 years prior to eoCRC diagnosis will be collected through an online platform.
  • at least 600 Healthy controls (HCs) totally (200 at IRCCS San Raffaele Scientific Institute), matched by age (matching range ± 5 years) and sex with eoCRCs will be prospectively enrolled. Healthy volunteers will be mainly enrolled among workers within the participating hospital center, followed regularly by preventive medicine. This enrollment will be carried out by e-mail invitation disseminated through the hospital's official mailing list. The enrolled healthy volunteers will perform fecal occult blood test as an additional procedure and will be enrolled if this test is negative. Retrospective data (dietary and lifestyle factors) related to the 2 years prior to recruitment will be collected through an online platform.

The online platform will be divided into two separate sections: (i) one completed by cases / controls, concerning the semi-quantitative food frequency questionnaire (SQFFQ), lifestyle habits and anthropometric data; (ii) one completed by doctors, concerning clinical data.

The semi-quantitative food frequency approach will ask to report their usual frequency of consumption of each food and drink, referred to the two years before eoCRC onset, following detailed oral and written instructions from the members of the study team. Information collected will concern types, amount and frequency of consumption of food and drinks, types of seasoning, and methods of cooking. A computer-administered instrument will allow the respondent to select the food consumed and the appropriate portion size from photographs on a screen reducing the burden of coding.

All cases and healthy controls will also provide a set of covariates as part of the online platform: date of birth, sex, ethnicity, weight (kg)/height (m)/BMI (kg/m2) at the time of eoCRC diagnosis and at 18 years old, country where the patient/healthy control lives permanently, tobacco smoking at the time of eoCRC diagnosis and at 18 years old, sitting time, TV-viewing time, moderate-to-vigorous physical activity (MVPA), waist circumference (cm), home blood pressure levels (mmHg), fasting blood glucose (mg/dl), regular consumption of aspirin/NSAID, calcium and folate supplements, oral contraceptive agents, post-menopausal hormones and years of consumptions, if the filled questionnaire reflects diet for the last 5-10 years before.

Other clinical data will be collected by doctors as part of the online platform: date of eoCRC diagnosis, symptoms at diagnosis, eoCRC localization, eoCRC stage, histological diagnosis, type of surgery and date (if performed), chemoterapy and radiotherapy (if performed), vital status and duration of follow-up, family history of CRC and other cancers (uterus, ovary, stomach, small intestine, urinary tract/bladder/kidney, bile ducts, brain, pancreas, skin tumors), type of germline pathogenetic variant (if performed).

4.6 Responsibilities of the Investigator(s) The Investigator(s) undertake(s) to perform the study in accordance with this Protocol, Good Clinical Practice and the applicable regulatory requirements.

The Investigator is required to ensure compliance with the investigational schedule, and procedures required by the protocol.

The Investigator agrees to provide all information requested in the Case Report Form -CRF- in an accurate and legible manner.

ETHICAL CONSIDERATIONS Ethical conduct of the study The study will be performed according the ethical principles laid down in the latest accepted version of the Declaration of Helsinki.

Patient information and informed consent Each subject/patient will be informed about the modalities of the clinical study in accordance with the enclosed patient information. The subject/patient is to be informed both in writing and verbally by the investigating physician. The subject/patient must be given opportunity to decide whether or not to participate in this study and to ask questions concerning this. It must also be made clear to the subject/patient that he/she can withdraw from the study at any time without giving reasons and that he/she will not be in any way disadvantaged by this. The points mentioned in the information sheet must be communicated to the patient in language he/she understands. The informing physician and the patient must each personally date and sign an informed consent form with a declaration on data privacy. Any informed consent will be part of the investigator's file and retained with it. The subject/patient will retain a copy of the patient information.

Data management The personal data will be recorded in the electronic CRF designed for this study. All CRF will be checked for completeness, plausibility, and compliance with the ICH guidelines and the institutional Standard Operating Procedures (SOPs).

The personal data will be identified with a code (see section 6.7) not allowing directly trace the identity of the patients/individuals, except in case of need. In all phases of collection and processing of personal data, suitable measures will be adopted to guarantee their protection from the risks of unauthorized access, theft or loss, also through the use of encryption techniques, identification codes or other solutions that allow identify the interested parties only in case of need and to those who are expressly authorized to access them, in order to minimize the risks of accidental knowledge and unauthorized or abusive access to data. The genetic and clinical data of the interested parties are, however, treated separately from other "common" personal data (name, surname, etc.), which allow the interested parties to be directly identified.

The collection, management and analysis of data will take place in a way that guarantees the confidentiality of the subject's identity and will follow the General Data Protection Regulations (GDPR).

With regard to the possible transfer of data to third countries, the processing will take place according to one of the methods permitted by current law, such as the consent given by the patients/individuals, the adoption of Standard Clauses approved by the European Commission, the selection of subjects adhering to international programs for the free circulation of data (eg EU-USA Privacy Shield) or operating in countries considered safe by the European Commission.

All analyses will be performed within respective limitations of each ethics committee approval and in accordance with good clinical practice and the Declaration of Helsinki.

Sample size

SQFFQ Validation study:

100 subjects from each country, free from overt disease and in equal numbers of each gender.

Case-control study:

Power analysis for odds ratios calculation The odds ratios of eoCRC for different exposition factors will be calculated.

For this purpose, a power analysis is performed, based on the following parameters:

  • Significance level (alpha, 1 type error probability) = 0.05 (two tails test)
  • Power of the analysis = 80%
  • Number of controls per case = 2
  • Minimum Odds Ratio to detect = 2
  • Proportion of exposed in the general population The proportion of exposed individuals in the general population depends on the considered exposition factors (such as a specific diet habit, alcohol consumption, etc.): for this reason, the sample size was calculated for different exposition proportions, varying from 5% to 95%.

Statistical analysis

SQFFQ validation Study:

The validity of the SQFFQ will be computed by calculating the Spearman correlation coefficients between individual food groups intakes from SQFFQ and the average of three 24hDR food groups intakes as the reference method.

The percentage of the agreement as the proportions of individuals who were classified correctly into the same or adjacent quintile for validity analyses will be calculated.

Case-control Study:

In the case-control study, an association between eoCRC and dietary habits (or other exposition factors such as alcohol consumption, smoking habits, etc.) will be estimated using logistic regression and odds ratio calculation. Multivariate logistic regression models will be used to examine to what extent eoCRC development can be 'explained' by variations in eating habits. The stratified analysis will also be performed by considering only a specific gender and/or other grouping variables of interest such as age, age at diagnosis. The effects of potential confounders other than matching criteria (e.g., smoking, physical activity, etc.) will also be estimated and taken into account. All analyses are based on a conservative estimate of eoCRC cancer cases, with at least 2 controls per case.

Being tested
Semi Quantitative Food Frequency Questionnaire (SQFFQ)
Keywords
Early onset, Young onset, Young adult, Colon cancer, Rectal cancer, Cancer genetics, Cancer risk factors, Diet
Medical subject headings
Colorectal Neoplasms, Feeding Behavior, Risk Reduction Behavior, Colonic Neoplasms, Rectal Neoplasms

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Semi Quantitative Food Frequency Questionnaire (SQFFQ)Behavioural

    The SQFFQ quantifies the frequency of consumption of each food and drink and the following list of variables:

    • date of birth
    • sex
    • ethnicity
    • weight (kg)
    • height (m)
    • BMI (kg/m2) at the time of eoCRC diagnosis and at 18 years old
    • country where they live permanently
    • tobacco smoking at the time of eoCRC diagnosis and at 18 years old
    • sitting time
    • TV-viewing time
    • moderate-to-vigorous physical activity (MVPA)
    • waist circumference (cm)
    • home blood pressure levels (mmHg)
    • fasting blood glucose (mg/dl)
    • regular consumption of aspirin/NSAID and years of consumptions
    • calcium and folate supplements and years of consumptions
    • oral contraceptive agents and years of consumptions
    • post-menopausal hormones and years of consumptions
Study groups in NCT05732623
Study groupRoleWhat they receive
Early onset colorectal cancerPatients with colorectal cancer diagnosed before the age of 50 years
Receives: Behavioral: Semi Quantitative Food Frequency Questionnaire (SQFFQ)
ControlIndividuals meeting all the following: * aged <50 years * no history of colorectal cancer * at least one negative screening test (at least a fecal occult blood test with high sensitivity)
Receives: Behavioral: Semi Quantitative Food Frequency Questionnaire (SQFFQ)

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Diet and the risk of eoCRC

    To quantify the relative risk of early-onset colorectal cancer for specific dietary and lifestyle risk factors (including the risk for eoCRC for

    • tobacco smoking at the time of eoCRC diagnosis and at 18 years old
    • alcohol consumption
    • physical activity
    • sex
    • ethnicity
    • BMI at the time of eoCRC diagnosis and at 18 years old
    • country of origin
    • Daily sitting time
    • Daily TV-viewing time
    • Daily moderate-to-vigorous physical activity (MVPA)
    • waist circumference (cm)
    • home blood pressure levels (mmHg)
    • Fasting blood glucose (mg/dl)
    • Regular consumption of aspirin/NSAID
    • Regular consumption of calcium and folate supplements
    • Regular use of oral contraceptive agents and years of consumptions
    • Regular use of post-menopausal hormones and years of consumptions Results will be stratified by countries where the incidence of eoCRC is increasing versus stable/decreasing

    Measured: 10 years

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted17 Feb 2023
  2. Study start5 Dec 2022
  3. Primary completionJan 2030 (estimated)
  4. Study completionJan 2035 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Case-control
Time perspective
Prospective
Enrolment
2,300 participants (estimated)
Target duration
10 Years
IDs, dates and publications
ClinicalTrials.gov ID
NCT05732623
Sponsor's protocol ID
DEMETRA2020.0001
Acronym
DEMETRA
Status last verified
Apr 2026
First submitted
27 Jan 2023
Last updated
24 Apr 2026
Results posted
No
Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
Yes: Individual participant data may be made available upon reasonable request

Publications

  • Russo AG, Andreano A, Sartore-Bianchi A, Mauri G, Decarli A, Siena S. Increased incidence of colon cancer among individuals younger than 50 years: A 17 years analysis from the cancer registry of the municipality of Milan, Italy. Cancer Epidemiol. 2019 Jun;60:134-140. doi: 10.1016/j.canep.2019.03.015. Epub 2019 Apr 18.

    PubMed 31005829
  • Zorzi M, Dal Maso L, Francisci S, Buzzoni C, Rugge M, Guzzinati S; AIRTUM Working Group. Trends of colorectal cancer incidence and mortality rates from 2003 to 2014 in Italy. Tumori. 2019 Oct;105(5):417-426. doi: 10.1177/0300891619838336. Epub 2019 Mar 27.

    PubMed 30917756
  • Zorzi M, Cavestro GM, Guzzinati S, Dal Maso L, Rugge M; AIRTUM Working Group. Decline in the incidence of colorectal cancer and the associated mortality in young Italian adults. Gut. 2020 Oct;69(10):1902-1903. doi: 10.1136/gutjnl-2019-320406. Epub 2019 Dec 16. No abstract available.

    PubMed 31843788
  • Wang L, Lo CH, He X, Hang D, Wang M, Wu K, Chan AT, Ogino S, Giovannucci EL, Song M. Risk Factor Profiles Differ for Cancers of Different Regions of the Colorectum. Gastroenterology. 2020 Jul;159(1):241-256.e13. doi: 10.1053/j.gastro.2020.03.054. Epub 2020 Apr 1.

    PubMed 32247020
  • Zhong Y, Zhu Y, Li Q, Wang F, Ge X, Zhou G, Miao L. Association between Mediterranean diet adherence and colorectal cancer: a dose-response meta-analysis. Am J Clin Nutr. 2020 Jun 1;111(6):1214-1225. doi: 10.1093/ajcn/nqaa083.

    PubMed 32359135
  • Keum N, Giovannucci E. Global burden of colorectal cancer: emerging trends, risk factors and prevention strategies. Nat Rev Gastroenterol Hepatol. 2019 Dec;16(12):713-732. doi: 10.1038/s41575-019-0189-8. Epub 2019 Aug 27.

    PubMed 31455888
  • Tabung FK, Brown LS, Fung TT. Dietary Patterns and Colorectal Cancer Risk: A Review of 17 Years of Evidence (2000-2016). Curr Colorectal Cancer Rep. 2017 Dec;13(6):440-454. doi: 10.1007/s11888-017-0390-5. Epub 2017 Oct 17.

    PubMed 29399003
  • Ahnen DJ, Wade SW, Jones WF, Sifri R, Mendoza Silveiras J, Greenamyer J, Guiffre S, Axilbund J, Spiegel A, You YN. The increasing incidence of young-onset colorectal cancer: a call to action. Mayo Clin Proc. 2014 Feb;89(2):216-24. doi: 10.1016/j.mayocp.2013.09.006. Epub 2014 Jan 4.

    PubMed 24393412
  • Chang DT, Pai RK, Rybicki LA, Dimaio MA, Limaye M, Jayachandran P, Koong AC, Kunz PA, Fisher GA, Ford JM, Welton M, Shelton A, Ma L, Arber DA, Pai RK. Clinicopathologic and molecular features of sporadic early-onset colorectal adenocarcinoma: an adenocarcinoma with frequent signet ring cell differentiation, rectal and sigmoid involvement, and adverse morphologic features. Mod Pathol. 2012 Aug;25(8):1128-39. doi: 10.1038/modpathol.2012.61. Epub 2012 Apr 6.

    PubMed 22481281
  • Araghi M, Soerjomataram I, Bardot A, Ferlay J, Cabasag CJ, Morrison DS, De P, Tervonen H, Walsh PM, Bucher O, Engholm G, Jackson C, McClure C, Woods RR, Saint-Jacques N, Morgan E, Ransom D, Thursfield V, Moller B, Leonfellner S, Guren MG, Bray F, Arnold M. Changes in colorectal cancer incidence in seven high-income countries: a population-based study. Lancet Gastroenterol Hepatol. 2019 Jul;4(7):511-518. doi: 10.1016/S2468-1253(19)30147-5. Epub 2019 May 16.

    PubMed 31105047
  • Vuik FE, Nieuwenburg SA, Bardou M, Lansdorp-Vogelaar I, Dinis-Ribeiro M, Bento MJ, Zadnik V, Pellise M, Esteban L, Kaminski MF, Suchanek S, Ngo O, Majek O, Leja M, Kuipers EJ, Spaander MC. Increasing incidence of colorectal cancer in young adults in Europe over the last 25 years. Gut. 2019 Oct;68(10):1820-1826. doi: 10.1136/gutjnl-2018-317592. Epub 2019 May 16.

    PubMed 31097539
  • Siegel RL, Torre LA, Soerjomataram I, Hayes RB, Bray F, Weber TK, Jemal A. Global patterns and trends in colorectal cancer incidence in young adults. Gut. 2019 Dec;68(12):2179-2185. doi: 10.1136/gutjnl-2019-319511. Epub 2019 Sep 5.

    PubMed 31488504
  • Khan NA, Hussain M, ur Rahman A, Farooqui WA, Rasheed A, Memon AS. Dietary Practices, Addictive Behavior and Bowel Habits and Risk of Early Onset Colorectal Cancer: a Case Control Study. Asian Pac J Cancer Prev. 2015;16(17):7967-73. doi: 10.7314/apjcp.2015.16.17.7967.

    PubMed 26625827
  • Song M, Chan AT. Environmental Factors, Gut Microbiota, and Colorectal Cancer Prevention. Clin Gastroenterol Hepatol. 2019 Jan;17(2):275-289. doi: 10.1016/j.cgh.2018.07.012. Epub 2018 Jul 18.

    PubMed 30031175
  • Nimptsch K, Malik VS, Fung TT, Pischon T, Hu FB, Willett WC, Fuchs CS, Ogino S, Chan AT, Giovannucci E, Wu K. Dietary patterns during high school and risk of colorectal adenoma in a cohort of middle-aged women. Int J Cancer. 2014 May 15;134(10):2458-67. doi: 10.1002/ijc.28578. Epub 2013 Nov 25.

    PubMed 24493161

Questions about this trial

What is this clinical trial studying?

An observational study of Colorectal Cancer and Early Onset Colorectal Cancer, run by San Raffaele University at 8 sites in 6 countries.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 3 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: looking for participants now, as of the sponsor's last update on 24 Apr 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 8 sites in United States, Germany, Finland, Italy, Norway and 1 more country. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

Contact Giulia Martina Cavestro, MD PhD (0226435508 ext. +39, cavestro.giuliamartina@hsr.it), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Diet and the risk of eoCRC (time frame: 10 years). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT05732623, which also lists 32 linked publications.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 24 Apr 2026.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in